Pentoxifylline plus mesalamine for adults with mild-to-moderate ulcerative colitis
Official title: Clinical Study Evaluating Safety and Efficacy of Pentoxifylline in Patients With Ulcerative Colitis
Run by Tanta University · NCT07349472 · Data updated 2026-11-12
This study will test whether adding pentoxifylline to standard mesalamine helps adults with mild to moderate ulcerative colitis have fewer symptoms and less inflammation.
Quick facts
| Phase | Phase 2 |
|---|---|
| Study type | Interventional |
| Ages | 18 Years to 70 Years |
| Sex | All |
| Enrollment | 60 (estimated) |
| Sponsor | Tanta University Academic / other |
| Locations | 1 site (Al Fayyum) |
| Status | Recruiting |
| Started | January 20, 2026 |
| Main results expected | January 20, 2027 |
| Study ends | February 20, 2027 |
| Registry record updated | April 15, 2026 |
| Trial ID | NCT07349472 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults with mild-to-moderate ulcerative colitis who are not taking systemic steroids, immunosuppressives, or biologic therapies and who can comply with pregnancy-prevention requirements are appropriate candidates.
✕Probably not a fit
Patients with severe ulcerative colitis, those on biologics or immunosuppressives, people with uncontrolled diabetes or significant liver/kidney disease, pregnant or breastfeeding women, and those allergic to the study drugs are unlikely to benefit from participation.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This phase 2 interventional trial gives pentoxifylline alongside mesalamine to adults with mild-to-moderate ulcerative colitis and monitors clinical response and safety. Eligible participants are 18 or older, not pregnant, and not using systemic steroids, immunosuppressives, or biological therapies. Key exclusions include severe UC, diabetes, significant liver or kidney dysfunction, colorectal cancer, substance addiction, and known allergies to the study drugs. Outcomes will focus on symptom changes, tolerability, and adverse events during the treatment period.
Why it matters
Potential benefit: If successful, adding pentoxifylline could reduce colon inflammation and improve symptoms for people with mild-to-moderate UC, offering a low-cost oral treatment option.
How similar studies have gone: Pentoxifylline has shown anti-inflammatory effects in small studies of other inflammatory conditions and limited IBD data, but robust evidence of benefit in ulcerative colitis is not yet established.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Age ≥ 18 years * Both male and female will be included * Negative pregnancy test and effective contraception. * Mild and moderate UC patients Exclusion Criteria: * Breast feeding * Significant liver and kidney function abnormalities * Diabetic patients * Colorectal cancer patients * Patients with severe UC * Patients taking rectal or systemic steroids * Patients taking immunosuppressives or biological therapies * Addiction to alcohol and / or drugs * Known allergy to the studied medications
Where it's running
-
Fayoum University
Al Fayyum, Egypt Recruiting
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Long-Term Guselkumab Use in Adults with Inflammatory Bowel Disease
This study looks at how long adults with Crohn's disease or ulcerative colitis stay on guselkumab in real-world care.
-
Intestinal ultrasound-guided management for inflammatory bowel disease
This study tests if adding point-of-care intestinal ultrasound at every visit changes treatment decisions for adults with Crohn’s disease or ulcerative colitis undergoing disease assessment.
-
Resting energy use in kids with inflammatory bowel disease
This multicenter study will test the resting energy expenditure of children aged 6–17 with new IBD diagnoses to see how it relates to disease activity and treatment.
-
Active video education by disease subtype to improve bowel prep before colonoscopy
We’re testing whether adding subtype-specific video education to standard prep improves bowel cleanliness in adults with IBD undergoing colonoscopy.
-
Intestinal ultrasound to predict relapse in Crohn's disease patients in deep remission.
This project will try to see if a noninvasive transabdominal ultrasound can predict relapses in adults with Crohn's disease who are currently in deep remission.
-
Ath-063: Testing a new treatment for moderately to severely active ulcerative colitis in patients who have tried other biologics
This study tests ATH-063 to see if it helps people with moderate to severe ulcerative colitis who did not respond to or relapsed after prior biologic therapy.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.